{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:31:44Z","timestamp":1793442704352,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011719","name":"Bone Cancer Research Trust","doi-asserted-by":"publisher","award":["BCRT\/9824"],"award-info":[{"award-number":["BCRT\/9824"]}],"id":[{"id":"10.13039\/100011719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011704","name":"Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","award":["PCRF 2022 (A010339)"],"award-info":[{"award-number":["PCRF 2022 (A010339)"]}],"id":[{"id":"10.13039\/100011704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008167","name":"Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009756","name":"Sarcoma UK","doi-asserted-by":"publisher","award":["SUK23.2024"],"award-info":[{"award-number":["SUK23.2024"]}],"id":[{"id":"10.13039\/100009756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002203","name":"The Brain Tumour Charity","doi-asserted-by":"publisher","award":["QfC_2022_10657"],"award-info":[{"award-number":["QfC_2022_10657"]}],"id":[{"id":"10.13039\/501100002203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115414","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:47:56Z","timestamp":1790462876000},"page":"115414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Collagen targeting IL-12 combined with Doxorubicin enhances the anti-tumor effect against osteosarcoma"],"prefix":"10.1016","volume":"399","author":[{"given":"Takumi","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Noblecourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chuan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanatsu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Larkeryd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3354-6264","authenticated-orcid":false,"given":"Kazunori","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anguraj","family":"Sadanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115414_bb0005","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2026.115414_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-0284-9_1","article-title":"The epidemiology of osteosarcoma","volume":"152","author":"Ottaviani","year":"2009","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.jconrel.2026.115414_bb0015","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115414_bb0020","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1038\/s41598-024-57527-8","article-title":"Identification of an early survival prognostic gene signature for localized osteosarcoma patients","volume":"14","author":"Patel","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115414_bb0025","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2014a report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-025-07992-2","article-title":"The tumor microenvironment of metastatic osteosarcoma in the human and canine lung","volume":"8","author":"McGee","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1117867","article-title":"Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities","volume":"13","author":"Du","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jconrel.2026.115414_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0060","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0306180","article-title":"High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin","volume":"81","author":"Yang","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115414_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27227","article-title":"Immunotherapy for osteosarcoma: where do we go from here?","volume":"65","author":"Wedekind","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2026.115414_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/srep30093","article-title":"Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma","volume":"6","author":"Koirala","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115414_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040976","article-title":"The osteosarcoma microenvironment: a complex but targetable ecosystem","volume":"9","author":"Corre","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.115414_bb0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/01.cco.0000432522.16734.2d","article-title":"WHO classification of soft tissue and bone, fourth edition: summary and commentary","volume":"25","author":"Rosenberg","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.871076","article-title":"Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2026.115414_bb0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0125","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115414_bb0130","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0135","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.4049\/jimmunol.153.4.1697","article-title":"Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production","volume":"153","author":"Nastala","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.omto.2020.11.003","article-title":"Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma","volume":"20","author":"Zalacain","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.jconrel.2026.115414_bb0145","article-title":"Delivery of IL-12 by neoantigen-reactive T cells promotes antitumor immunity in murine osteosarcoma mode","volume":"5","author":"Tian","year":"2025","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.jconrel.2026.115414_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009712","article-title":"Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models","volume":"12","author":"Fabian","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115414_bb0155","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115414_bb0160","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115414_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0170","first-page":"1","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115414_bb0175","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157448","article-title":"Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity","volume":"7","author":"Hong","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.115414_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3259","article-title":"Targeted antibody and cytokine cancer immunotherapies through collagen affinity","volume":"11","author":"Ishihara","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115414_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115414_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw6081","article-title":"Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy","volume":"5","author":"Sasaki","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115414_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172179","article-title":"Comparative shotgun proteomics reveals the characteristic protein signature of osteosarcoma subtypes","volume":"12","author":"Alaa","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.115414_bb0205","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1021\/acs.jproteome.4c01060","article-title":"Systematic comparison of bone proteome extraction methods to allow for integrated proteomics-metabolomics correlation","volume":"24","author":"Wiltzsch","year":"2025","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jconrel.2026.115414_bb0210","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1021\/pr200522n","article-title":"Unraveling the human bone microenvironment beyond the classical extracellular matrix proteins: a human bone protein library","volume":"10","author":"Alves","year":"2011","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jconrel.2026.115414_bb0215","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/sicotj\/2017028","article-title":"Osteosarcoma: a comprehensive review","volume":"4","author":"Misaghi","year":"2018","journal-title":"SICOT J."},{"key":"10.1016\/j.jconrel.2026.115414_bb0220","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-22-2642","article-title":"Discovery and targeting of a noncanonical mechanism of sarcoma resistance to ADI-PEG20 mediated by the microenvironment","volume":"29","author":"Rogers","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115414_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.367","article-title":"P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development","volume":"7","author":"Velletri","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.115414_bb0230","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006767007547","article-title":"An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential","volume":"18","author":"Khanna","year":"2000","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.jconrel.2026.115414_bb0235","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ph18040520","article-title":"Advancements in osteosarcoma therapy: overcoming chemotherapy resistance and exploring novel pharmacological strategies","volume":"18","author":"Zhra","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2026.115414_bb0245","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41419-020-03133-1","article-title":"Synergetic therapy of glioma mediated by a dual delivery system loading alpha-mangostin and doxorubicin through cell cycle arrest and apoptotic pathways","volume":"11","author":"Nie","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.115414_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223614","article-title":"Depletion of R270C mutant p53 in osteosarcoma attenuates cell growth but does not prevent invasion and metastasis in vivo","volume":"11","author":"Shimizu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.115414_bb0255","first-page":"114","article-title":"P53 is required for Doxorubicin-induced apoptosis via the TGF-beta signaling pathway in osteosarcoma-derived cells","volume":"6","author":"Sun","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115414_bb0260","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.immuni.2018.03.015","article-title":"KLRG1(+) effector CD8(+) T cells lose KLRG1, differentiate into all memory T cell lineages, and convey enhanced protective immunity","volume":"48","author":"Herndler-Brandstetter","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115414_bb0265","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200264","article-title":"Tumor-infiltrating dendritic cell states are conserved across solid human cancers","volume":"218","author":"Gerhard","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1471-4906(03)00111-X","article-title":"What\u2019s the difference between CD80 and CD86?","volume":"24","author":"Sansom","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0275","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004561","article-title":"Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies","volume":"10","author":"Minnar","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115414_bb0285","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24786","article-title":"Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy","volume":"2","author":"Ma","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115414_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.496","article-title":"TNF\/TNF-R1 pathway is involved in doxorubicin-induced acute sterile inflammation","volume":"4","author":"Kaczmarek","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.115414_bb0295","first-page":"399","article-title":"Effects of dulaglutide in doxorubicin induced renal toxicity in rats","volume":"19","author":"Hama Said","year":"2025","journal-title":"Biologics"},{"key":"10.1016\/j.jconrel.2026.115414_bb0300","series-title":"Doxorubicin","author":"Johnson-Arbor","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115414_bb0305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.115414_bb0310","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1007\/s00210-025-04125-8","article-title":"Chemoimmunotherapy synergism: mechanisms and clinical applications","volume":"398","author":"Shaik","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115414_bb0315","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0320","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115414_bb0325","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1535370217736512","article-title":"Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples","volume":"242","author":"Ho","year":"2017","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.jconrel.2026.115414_bb0330","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13046-021-02133-z","article-title":"Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy","volume":"40","author":"Jensen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115414_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413523","article-title":"The multifaced role of collagen in cancer development and progression","volume":"25","author":"Lo Buglio","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115414_bb0340","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115414_bb0345","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<720::AID-IJC10>3.0.CO;2-5","article-title":"Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin","volume":"77","author":"Zagozdzon","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115414_bb0350","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejpb.2022.07.002","article-title":"Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type Macrophages","volume":"177","author":"Li","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:48:42Z","timestamp":1793440122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926008187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":70,"alternative-id":["S0168365926008187"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115414","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Collagen targeting IL-12 combined with Doxorubicin enhances the anti-tumor effect against osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115414"}}